• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Alto Neuroscience Inc.

    10/27/25 5:17:59 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANRO alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001999480
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Alto Neuroscience, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Alto Neuroscience, Inc.
    Street Address 1 Street Address 2
    650 CASTRO STREET, SUITE 450
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    MOUNTAIN VIEW CALIFORNIA 94041 (650) 200-0412

    3. Related Persons

    Last Name First Name Middle Name
    Etkin Amit
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hanley Michael
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Savitz Adam
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Smith Nicholas C.
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    York Gwill
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cox Christopher Nixon
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Dreyfus Andrew
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Manji Husseini
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sanchez Raymond
    Street Address 1 Street Address 2
    c/o Alto Neuroscience, Inc. 650 Castro St, Suite 450
    City State/Province/Country ZIP/PostalCode
    Mountain View CALIFORNIA 94041
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
    X Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
    X No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
       Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-10-21    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $49,999,533 USD
    or    Indefinite
    Total Amount Sold $49,999,533 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Pre-Funded Warrants to purchase 4,622,251 shares of common stock may be exercised in the future, subject to beneficial ownership limitations, for total additional compensation of $462.23.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    7

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Alto Neuroscience, Inc. /s/ Nicholas C. Smith Nicholas C. Smith Chief Financial Officer and Chief Business Officer 2025-10-27

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $ANRO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANRO

    DatePrice TargetRatingAnalyst
    9/29/2025$15.00Buy
    Chardan Capital Markets
    10/23/2024$29.00 → $4.00Outperform → Neutral
    Wedbush
    10/23/2024Buy → Neutral
    Rodman & Renshaw
    9/3/2024$29.00Outperform
    Wedbush
    2/27/2024Outperform
    William Blair
    2/27/2024Outperform
    TD Cowen
    2/27/2024$32.00Outperform
    Robert W. Baird
    2/27/2024$33.00Buy
    Jefferies
    More analyst ratings

    $ANRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF MEDICAL OFFICER Savitz Adam bought $190,833 worth of shares (15,000 units at $12.72) (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    7/11/24 4:15:04 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smith Nicholas Conrad bought $100,628 worth of shares (6,150 units at $16.36), increasing direct ownership by 30% to 26,866 units (SEC Form 4)

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    4/1/24 4:15:30 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    SEC Filings

    View All

    SEC Form D filed by Alto Neuroscience Inc.

    D - Alto Neuroscience, Inc. (0001999480) (Filer)

    10/27/25 5:17:59 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Alto Neuroscience Inc.

    SCHEDULE 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

    10/27/25 4:02:16 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

    10/20/25 4:01:59 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sanchez Ramiro

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    8/14/25 5:22:27 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sanchez Ramiro

    3 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    8/14/25 5:21:57 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF OPERATING OFFICER Hanley Jr. Michael Conick

    4 - Alto Neuroscience, Inc. (0001999480) (Issuer)

    7/8/25 5:22:49 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ANRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alto Neuroscience to Participate in Upcoming Investor Conferences

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 10:00-10:30 AM ET Location: New York, New York Jefferies London Healthcare Conference, November 17-20, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date & Time: Monday, November 17 at 3:30-3:55 P

    10/28/25 7:34:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Announces $50 Million Private Placement Financing

    – Financing led by Perceptive Advisors with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of this financing to accelerate development of ALTO-207 in Treatment Resistant Depression – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately $50 million, before deducting offering expenses. The financing wa

    10/20/25 7:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

    – Successful outcome from recent FDA meeting guides Alto's plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to initiate a Phase 3 study by early 2027 – – Positive results from blinded pharmacokinetic (PK) analyses across ongoing Phase 2 studies for ALTO-100 and ALTO-101 support clinical study execution efforts aimed at improving patient compliance – – Alto maintains cash guidance into 2028, now including additional development activities for ALTO-207 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for n

    10/20/25 7:01:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Alto Neuroscience with a new price target

    Chardan Capital Markets initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $15.00

    9/29/25 9:57:16 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience downgraded by Wedbush with a new price target

    Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

    10/23/24 7:37:30 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience downgraded by Rodman & Renshaw

    Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

    10/23/24 6:52:50 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Leadership Updates

    Live Leadership Updates

    View All

    Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

    Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries. "We are delighted to welcome Ray to our Board of Directors as we continue advancing multiple clinical-stage precision psychiatry programs," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "Ray brings an impress

    8/13/25 8:03:00 AM ET
    $ANRO
    $CERE
    $RAPP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Christopher Nixon Cox Named Chairman of High-Trend International Group

    SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

    3/13/25 9:00:00 AM ET
    $ANRO
    $HTCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Marine Transportation
    Consumer Discretionary

    Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

    – Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) today announced the expansion of the Company's leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto's COO, M

    5/21/24 8:05:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Alto Neuroscience Inc.

    SC 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/14/24 5:46:11 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/14/24 7:00:29 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Alto Neuroscience Inc.

    SC 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

    11/12/24 9:50:14 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANRO
    Financials

    Live finance-specific insights

    View All

    Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study expected to initiate by mid-2026 – – Topline data expected from Phase 2 proof-of-concept (POC) trial of ALTO-101 in schizophrenia in the second half of 2025; Phase 2b topline data readouts include ALTO-300 in MDD expected mid-2026 followed by ALTO-100 in bipolar depression expected in the sec

    8/13/25 4:10:00 PM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

    –  Compelling PAX-D results guided Alto's acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – –  Alto plans to collaborate with National Health Service, PAX-D clinical sites for the planned Phase 2b trial of ALTO-207, designed to be a potentially pivotal study; trial expected to initiate by mid-2026 – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-r

    6/30/25 8:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

    – ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

    6/3/25 6:03:00 AM ET
    $ANRO
    Biotechnology: Pharmaceutical Preparations
    Health Care